Milestone Pharmaceuticals: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
Milestone Pharmaceuticals (NASDAQ:MIST) reported Q4 earnings with an EPS of $-0.32, missing estimates by -3.0% and experiencing a revenue decline of $3.50 million from the previous year. This follows a pattern from the last quarter where despite beating EPS estimates, the share price dropped by 4.0% the next day.
March 21, 2024 | 1:10 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Milestone Pharmaceuticals reported a Q4 EPS of $-0.32, missing estimates by -3.0%, with a significant revenue decline from the previous year.
The missed earnings estimate and the year-over-year revenue decline are likely to negatively impact investor sentiment towards MIST in the short term. Historical context from the last quarter shows that beating EPS estimates did not prevent a share price drop, suggesting that the market may react unfavorably to this earnings report.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100